drugset / Trial / NCT01016249

Nebulized 5% Hypertonic Saline for the Treatment of Bronchiolitis

NCT01016249 ↗

Phase 4 Completed 187 enrolled Hamad Medical Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators reasoned that a hypertonic saline concentration higher than 3% could be safe and more efficacious in the treatment of bronchiolitis, alleviating severe symptoms and preventing the need for hospitalization in some instances.

Timeline

Start
2007-04
Primary completion
2008-04
Completion
2009-04

Outcome

Met primary endpoint

paper At 48 hours, the mean severity score for the 5% saline group was 3.69+/-1.09, and that for the 0.9% saline group was 4.12+/-1.11 (P=.04 PMID 20646715 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Hypertonic saline Unknown 4 ml Inhaled
Subject sodium chloride Unknown 4 ml Inhaled
Background Epinephrine Other / unclassified 1.5 ml Inhaled

Indications